Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, 300, Guangzhou Road, 210029 Nanjing, People's Republic of China.
J Neurooncol. 2012 Jan;106(2):217-24. doi: 10.1007/s11060-011-0679-1. Epub 2011 Aug 13.
Gliomas are the most common type of malignant primary brain tumor. Despite advances in surgery, radiation therapy, and chemotherapy, the prognosis of patients with gliomas has not significantly improved. MicroRNAs (miRNAs), a class of non-coding RNAs, 21-25 nucleotides long, negatively regulate the expression of target genes by interacting with specific sites in mRNAs, and play a critical role in the development of gliomas. The EGFR/PTEN/AKT pathway is a promising target for anti-glioma therapy. Recent studies have showed that regulation of the EGFR/PTEN/AKT pathway by miRNAs plays a major role in glioma progression, indicating a novel way to investigate the tumorigenesis, diagnosis, and therapy of gliomas. Here, we focus on recent findings of miRNAs with respect to the EGFR/PTEN/AKT pathway in gliomas.
神经胶质瘤是最常见的原发性脑恶性肿瘤。尽管在手术、放射治疗和化学疗法方面取得了进展,但神经胶质瘤患者的预后并未显著改善。微小 RNA(miRNA)是一类长约 21-25 个核苷酸的非编码 RNA,通过与 mRNAs 中的特定位点相互作用,负调控靶基因的表达,在神经胶质瘤的发生发展中发挥着关键作用。EGFR/PTEN/AKT 通路是一种很有前途的抗神经胶质瘤治疗靶点。最近的研究表明,miRNA 对 EGFR/PTEN/AKT 通路的调节在神经胶质瘤的进展中起着重要作用,这为研究神经胶质瘤的发生、诊断和治疗提供了一种新的方法。在这里,我们重点介绍 miRNA 对 EGFR/PTEN/AKT 通路在神经胶质瘤中的最新发现。